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MECHANISMS OF MONONEGAVIRALES GENE EXPRESSION 
OLIVER JAMES HAYWARD 
ABSTRACT 
The Mononegavirales order unifies the non-segmented negative sense viruses 
(nsNSVs), including Marburgvirus (MARV) of the Filoviridae family and respiratory 
syncytial virus (RSV) of the Pneumoviridae. The mechanism of action of these viruses 
and how they infect cells are very similar, especially when focusing on their polymerases, 
which are distinct from those of eukaryotes and therefore possible targets for antiviral 
drugs. nsNSVs utilize a RNA-dependent RNA polymerase to either replicate the viral 
RNA genome or transcribe it into positive sense mRNA. Despite this, these two viruses 
result in very different, but equally devastating, effects in humans. Whereas MARV virus 
often results in rare but fatal hemorrhagic fevers, RSV is a common seasonal virus that 
can result in long term negative effects to respiratory health. These negative effects on 
public health demand extensive research in these two fields and a need to develop new 
technology and methods in order to uncover the missing pieces of viral gene expression. 
Specifically, the development of a MARV minigenome system would allow for increased 
testing of this virus outside of the confines of the biosafety level 4 (BSL-4) setting. By 
replacing MARV genes with reporter genes, but retaining the characteristic leader, 
intergenic, and trailer regions of the genome, tests involving site directed mutagenesis 
would reveal new insights into the crucial genomic elements needed for successful gene 
expression. Coupled with the transfection of the minigenome with plasmids coding for 
the crucial MARV proteins, artificial changes to the genome would lead to the presence 
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of absence of translated bioluminescent reporter proteins. Using these two viruses, this 
study attempted to find commonalities across families. Specifically, the goals of this 
research were twofold, to find the optimal ratio of MARV plasmids in the minigenome 
system to understand the effects of the stem-loop secondary structure of MARV mRNA 
transcripts as well as determine the tail length of the poly(A) tail of RSV mRNA 
transcripts using digestion and probing primers. Calculating the RSV poly(A) tail length 
would allow for further research into determining whether the MARV and RSV 
polymerase polyadenylates before or after it releases the transcript. Despite multiple 
failed attempts, transfections using pCAGGS plasmids and the eGFP monocistronic 
minigenome in a 6-well plate qualitatively demonstrated the need for pCAGGS-L 
plasmid concentration of 1000 ng/µl. Due to time constraints, the poly(A) tail length of 
the RSV NS-1 mRNA transcript could not be determined. Overall, this study focused on 
gaining new insights on the techniques and procedures necessary for conducting virus 
research in a biosafety level 2 (BSL-2) setting, as well as developing troubleshooting 
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The order Mononegavirales, established in 1991, has grown to contain eleven 
different viral families encompassing the linear, single-stranded, non-segmented negative 
strand ribonucleic acid (RNA) viruses (nsNSVs)1. This diverse order contains many 
notable human pathogens, such as Avian flu, Ebola virus (EBOV), Hendra, measles 
(MeV), mumps (MuV), and rabies1,2. Though distinct viruses, these species share a 
common viral genome structure, a single strand of RNA containing five to ten genes, 
which are translated by a RNA-dependent RNA polymerase (RdRp) in a highly 
conserved order1. The genome is either replicated via a positive sense RNA intermediate, 
to produce new genomes, or is transcribed into a series of mRNAs in a conserved order, 
which are then translated3–5. This polymerase is a key target for antiviral and vaccine 
research and development, as its structure and enzymatic reactions are crucial for the 
viral life cycle and are distinct from humans and other eukaryotes3.  
Despite extensive research on these notorious viruses, the relationship between 
gene expression and the elements of polymerase transcription remains poorly understood. 
To elucidate more information on this interaction, this study will investigate the influence 
of mRNA structure and the mechanisms of transcript release and polyadenylation across 
different families of the Mononegavirales order. By studying two Mononegavirales 
viruses, human respiratory syncytial virus (RSV) of Pneumoviridae and Marburg virus 
(MARV) of Filoviridae in parallel, this research will not only attempt to provide another 
bridge between the families of this diverse order, but will also allow for advancement of 




Elevated in 2016 from a subfamily within the Paramyxoviridae family, 
Pneumoviridae encapsulates nsNSVs often associated with respiratory infections in 
mammals and birds1. A member of this family, RSV, is a leading pathogen-specific cause 
of post-neonatal hospitalization and death worldwide, second only to malaria6,7. First 
isolated in 1955 from a chimpanzee with an upper respiratory tract infection during an 
outbreak at the Walter Reed Army Institute chimpanzee colony, this seasonal virus leads 
to common-cold-like symptoms, which can escalate to severe upper respiratory tract 
infections, such as bronchiolitis and pneumonia, and in rare cases, death2,8,9. Invading the 
apical surface of airway epithelium, RSV causes airway ciliate cell shedding leading to 
bronchiole and alveoli obstruction2,10. RSV is highly common and has infected most 
individuals by the age of two8. Symptoms usually occur within four to six days after 
infection, but are not considered to be persistent2,8. Reinfection is common, but not as 
severe, due to an incomplete acquired immune response8. 
RSV infections affect infants in their first year of life, and place the greatest 
burden on the developing world7. From a 2017 meta-analysis report on RSV, covering 55 
studies in 32 countries from 2002-2014, the global incidence rate of hospitalization was 
6.60 admissions per 1,000 children <1 year of age per year, with a global fatality rate of 
19.19 cases per 1,000 children <1 year of age per year6. Among the factors that make 
infants more susceptible to contracting RSV, such as low birth weight, maternal smoking 
and an absence of breastfeeding, prematurity places the child at most risk8. Due to 
reduced lung development and limited maternally transmitted antibodies, premature 
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infants <1 year of age saw a global incidence rate of RSV 3 times greater than the 
average, and 16 times higher than the rate for children less than 5 years old6. For those 
who do survive the infection, many have been shown to exhibit asthma and other 
hyperreactive airway conditions later in life8. Adults can still contract RSV, but the 
infection is most likely not the primary issue, and only severely affects those who are 
immunocompromised or frail, exhibit chronic pulmonary or circulatory disease, or live in 
a skilled nursing facility8.  
Classified as a Biosafety Level 2 (BSL-2) virus for its moderate threat to human 
health, RSV places a significant economic pressure not only on the healthcare system, but 
broadly in the way of lost income and productivity of parents who must care for their 
infants8. Without an effective antiviral or vaccine regimen, treatment for RSV is 
expensive and limited, costing upwards of 600 million dollars per year. Apart from 
supportive medical care, the monoclonal antibody immunoprophylactic Palivizumab 
(SynagisTM), is available not for disease prevention, but to restrict RSV replication in 
high risk premature and mature infants with congenital heart and lung defects, with 
chronic respiratory symptoms2,11. Administered intramuscularly, this drug has been 
shown to reduce RSV hospitalizations by 55% compared with placebo in a large double-
blind, multicenter study (n= 1502)7. Unfortunately, this drug has not yet been supported 
by sufficient epidemiological data to be mass distributed11. The high price and limited 
access also affects its ability to reach critical areas, such as the developing world. Due to 
the frequency of RSV infections, however, mounting pressure has been placed on 
pharmaceutical research to produce safe and efficacious options.  
 
4 
Whereas RSV is a moderate, but frequent, human health hazard, MARV is a 
highly dangerous, but exotic, microbe studied at the highest level of biosafety. Similar to 
its more well-known filovirus relative, EBOV, MARV is capable of producing large-
scale outbreaks of severe Marburg virus disease (MVD), with a case fatality rate up to 
90% in all age groups13. Affecting humans and susceptible non-human primates, viral 
infection leads to dysregulated and impaired coagulation and inflammatory responses, 
edema, hemorrhage, and immunosuppression, and ultimately resulting in multiorgan 
failure, shock and death13,14.  
Without any vaccine or antiviral treatment, MARV outbreaks have been 
particularly devastating. The first fatal cases in humans occurred in 1967, when African 
green monkeys imported from Uganda infected German and Serbian laboratory workers 
in Marburg, Germany15,16. This event additionally made MARV the first recorded 
filovirus to cause an epidemic outside Africa17. Since then, cases have been reported in 
other foreign locations such as the United States and the Netherlands, but have all been 
traced back to sub-Saharan Africa13,16. In 2017, the fifth Ugandan MARV outbreak in ten 
years hit two eastern districts, killing three people over the course of three weeks18. 
Additional outbreaks have also occurred in Angola and the Democratic Republic of the 
Congo, where primary transmission likely occurred from spillover between humans and 
the fruit bat Rousettus aegyptiacus, MARV’s natural reservoir13,14,19. Whether by 
exposure to these bats or their secretions, infection spread human-to-human and led to 
hundreds of cases, the worst instance being 252 affected patients at a 90% case fatality 
rate16. The disparity between this survival rate and the 22% case fatality rate achieved in 
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the 1967 outbreak may be due to different strain virulence or transmission routes, but 
could also indicate the positive influence of accessible, advanced and aggressive medical 
treatment on disease control, which is not readily available in the affected African 
regions20. 
As a major risk to national security and public health, MARV is classified as a 
Category A Priority Pathogen by the National Institute of Allergy and Infectious Diseases 
(NIAID) and a Biosafety Level 4 (BSL-4) pathogen and Select Agent by the Center for 
Disease Control (CDC). Funding for EBOV research has overshadowed MARV, but the 
threat of infection spread for a virus of this magnitude, be it through bioterrorism or 
through tourism within central Africa, has sparked research overall in this field and a 
demand for effective antiviral strategies15,21. 
Genome Structure and Replication Cycle 
The A2 strain RSV virion is a 15,222 base long genome enclosed in a filamentous 
or spherical lipid bilayer of 100-350 nanometers (nm) or 20-200 nm in diameter, 
respectively2 (Figure 1). RSV virus formation and regulation utilize eleven different 
proteins encoded from ten open reading frames (ORFs). These proteins, in the order of 
transcription, are the Non-Structural proteins (NS-1 and NS-2), Nucleocapsid protein (N), 
Phosphoprotein (P), Matrix protein (M), Small Hydrophobic protein (SH,) Glycoprotein 
(G), Fusion protein (F), M2-1, M2-2, and Large polymerase protein (L) (Figure 2)9. The 
three integral membrane proteins forming the outer lipid envelope are G, F, and SH22. 
Though F is involved in fusion, F and G are both responsible for receptor attachment of 
neutralization and protective antigens. Additionally, SH forms viroporins and pentameric 
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ion channels on the virion envelope22. M is an essential inner envelope membrane-
associated protein involved in mediating viral assembly and cytoplasmic membrane 
binding. N, P, L and M2-1 are the ribonucleocapsid proteins, which package the RNA 
genome22. N is a RNA-binding protein involved in encapsidation of the genome within a 
filamentous nucleocapsid, forming a characteristic “herringbone” pattern2. L and P are 
components of the RNA-dependent polymerase directly involved in RNA replication and 
transcription, coupled with the transcription processivity factor M2-1. M2-2 has been 
shown to switch RNA synthesis between replication and transcription23(p2). NS-1 and NS-
2 are the only nonstructural regulatory proteins involved in inhibiting apoptosis and 
antagonizing type I interferons (IFN), preventing the host cell from inhibiting viral 
replication24.  
 
Figure 1; RSV virion structure. The “herringbone” nucleocapsid structure consists of 
the single stranded negative sense RNA encapsidated by N protein and the association of 
the RSV polymerase complex, consisting of L, P, M2-1. This spherical outer lipid 
membrane, though host-derived, contains the three glycoproteins, F, G and SH. NS-1 and 






Figure 2; Schematic of the RSV genome. The RSV genome consists of 10 ORFs coding 
for 11 different proteins. The polymerase complex replicates the genome by first 
synthesizing the positive sense antigenome, which is directed by the le and tr regions, and 
ignores the gs (black) and ge (white) sequences. Monocistronic mRNA contain the 
individual capped and polyadenylated genes signaled by these gs and ge sequences, 
containing the ORF and flanking UTRs. Polycistronic, readthrough, mRNA would 
contain multiple ORFs, containing the entire gene sequence in between.  
 
The RSV replication cycle begins with F and G-mediated receptor attachment to 
the apical surface of a host cell. Through F mediated fusion, the nucleocapsids are able to 
enter the cytoplasm and group together to form highly ordered, crystalized inclusions, 
where RSV’s encoded polymerase can initiate transcription and replication25. The 
resulting mRNA is utilized by the host cell machinery, producing eleven different 
proteins. Viral assembly occurs at the plasma membrane, where budding is initiated by 
taking control of the host cell’s apical recycling endosomes26. Progeny virions are then 
able to exocytose through plasma membrane associated with lipid rafts, in order to infect 
new cells27.  
The 19.1 kilobase (kb) long MARV genome contains seven genes coding for 
seven different proteins. Together, all of these proteins form the MARV virion, a 
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ribonucleocapsid within a host-derived filamentous lipid membrane (Figure 3). The order 
of transcription produces mRNAs leading to formation of nucleoprotein (NP), viral 
protein 35 (VP35), viral protein 40 (VP40), glycoprotein (GP), viral protein 30 (VP30), 
viral protein 24 (VP24), and large polymerase protein (L) (Figure 4). Like the RSV 
protein N, NP functions to encapsidate the RNA antigenome and genome, forming the 
nucleocapsid with VP35, VP30, L and VP241. VP35 is a cofactor for L, the catalytic 
domain of the RNA-dependent polymerase, which recruits the polymerase to the 
nucleocapsid. VP35 is also similar to RSV NS-1 and NS-2 in its protective role as an IFN 
antagonist, blocking RNA recognition by host cell factors4,20. In addition, VP40 disrupts 
the host innate immune response by blocking phosphorylation of Janus kinase/Signal 
Transducer and Activator of Transcription (JAK/STAT), thereby inhibiting type I IFN 
signaling29. GP, MARV’s only transmembrane protein, is a receptor binding and 
attachment protein, which is also responsible for viral fusion with the endosomal 
compartment of the cellular membrane. VP30 and MARV’s second matrix protein, VP24, 





Figure 3; MARV virion structure. The single stranded MARV RNA (black) is 
encapsidated by NP (pink), forming the nucleocapsid along with VP24 (red) and VP30 
(green). The L polymerase subunit (dark blue), with its cofactor VP35 (dark gray) forms 
the polymerase complex. The inner lipid envelope consists of VP40 (light blue), with the 
outer lipid membrane (gray) forming a filamentous shape, studded with GP (yellow). 
Original image created by Brauberger17. 
 
 
Figure 4; Schematic of the MARV genome. The MARV genome consists of 7 ORFs 
coding for 7 different proteins. Though MARV has a similar polymerase replication and 
transcription process as RSV and other nsNSV, there is an overlap of the gs sequence for 




MARV virus enters its host cell through GP-mediated macropinocytosis or 
endocytosis20,30. GP attachment to cell surface proteins results in a structural 
conformation change of GP which allows for fusion with the cellular membrane. Once 
bound, the virion releases its nucleocapsids into the host cell cytoplasm, where the 
MARV RNA genome is transcribed and replicated by its polymerase. The resultant 
capped and polyadenylated mRNA is translated by the host cell’s machinery producing 
viral proteins, ultimately leading to the production of nucleocapsids, containing the RNA 
genome or antigenome. Highly organized inclusions within the cells result from grouping 
of these nucleocapsids, where maturation and genome replication occur. Once mature, 
nucleocapsids hijack the cell’s actin filament transport system to reach cellular budding 
sites at the filopodia plasma membrane or multivesicular bodies31. VP40-mediated 
budding of the nucleocapsid occurs by commandeering the host cell’s endosomal sorting 
complexes required for transport (ESCRT) system, further supported by NP, GP, and 
VP2420. Once released, the cycle can continue on to infect other cells.  
Despite their major differences in the public health realm, MARV and RSV share 
several common genomic features1. Transcription starts at a 3’ extragenic proximal 
promoter region, known as the leader (le)32. From there, the polymerase moves along the 
rest of the genome, consisting of 7 or 10 genes, respectively, flanked by short non-
transcribed regulatory cis-acting elements, and a 5’ extragenic region, known as the 
trailer (tr). Intergenic regions of 4-97 or 1-52 nucleotides lie between most of these gene 
sequences for MARV and RSV, respectively, but others do overlap33,34. Conserved gene 
start (gs) sequences before each gene allow the polymerase to generate monocistronic 
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mRNAs by directing RNA synthesis initiation, elongation and capping of the nascent 
mRNA. Conserved gene end (ge) sequences are located after each gene, and consist of 4-
7 nucleotide uridine residues, which signal polyadenylation, the addition of multiple 
adenine nucleotides to form a tail, and mRNA transcript release by the polymerase. The 
addition of a poly(A) tail to the 3’ end of nsNSV mRNA plays a role in transcription 
termination and protection from degradation enzymes before translation. By remaining 
attached to the genome after a ge sequence, the polymerase can scan along and locate the 
next gs sequence, reinitiating mRNA synthesis to transcribe monocistronic mRNAs in a 
start-stop fashion5,16,28. Due to inefficient termination at the ge sequence, however, 
nsNSV polymerases are also capable of producing polycistronic, or readthrough, 
mRNAs35. These transcripts contain upstream and downstream gene open reading frames 
as well as flanking non-coding untranslated regions and intergenic sequences. 
Alternatively, the polymerase can ignore all gene junction sequences between the leader 
and trailer in order to completely replicate the entire genome. Genome synthesis is 
signaled by the 3’ trailer promoter of this newly formed positive sense antigenome (ag), 
which provides the template for a new negative sense RNA strand. Actions of the 
polymerase in the realm of polyadenylation will be determined through analysis of these 
monocistronic and readthrough mRNAs.  
Scientific Proposal and Hypothesis 
Research on RSV and MARV will be possible primarily through the combined 
efforts of the Fearns and Mühlberger laboratories within the National Emerging 
Infectious Diseases Laboratories (NEIDL). With the successful purification of an 
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enzymatically active recombinant MARV polymerase and new permissions to 
experiment on BSL-4 pathogens, the Fearns and Mühlberger laboratories are able to 
expand its already substantial research on MARV and other filoviruses. The Fearns lab 
additionally complements this work by offering its proven expertise and refined 
techniques on RSV transcription and replication. The Fearns lab has successfully 
developed in vitro and minigenome assays with purified RdRp to study the interaction of 
the RSV RNA polymerase with the leader promoter region, for example, uncovering the 
position on the template at which transcription can begin, as well other synthesis 
activities that the polymerase can perform there36,37. Studying these viruses in parallel 
across two distinct laboratories working specifically on these targeted viruses, allows for 
the determination of replicable data and the dissemination of tried and tested techniques 
and ideas between labs. Notably, the development of rescued MARV gene plasmids by 
the Mühlberger lab allows for MARV research outside the BSL-4 setting and within the 
Fearns lab environment, offering a truly parallel investigation of RSV and MARV.  
Of the missing data regarding the nsNSV polymerase activity and gene 
expression, the polyadenylation mechanism is a significant mystery. Support for 
polyadenylation co-transcriptionally has been shown in studies on the readthrough 
mRNA of VSV, which contained approximately 30 to 1200 adenine nucleotides between 
each cistron37. The presence of this poly(A) tract indicated that the polymerase may 
perform reiterative transcription, or deliberate and controlled stuttering on the 4-7 
nucleotide uridine tract of the mRNA template before releasing the mRNA transcript38. 
VSV belongs to the Rhabdoviridae family, and differs from RSV, for example, in that its 
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L protein is able to initiate RNA synthesis without the P accessory proteins39. 
Additionally, intergenic polyadenylation has only been confirmed in VSV, despite 
targeted experiments on Sendai. Notably, research on Sendai virus demonstrated 
polyadenylation does not exist in readthrough mRNA. 
The much smaller ~50 nucleotide poly(A) tails of EBOV, however, may suggest a 
different method of polyadenylation40. Terminal transferase activity of the RSV and 
MARV polymerase has been identified by the Fearns Lab, suggesting the possibility that 
the complex does not stutter, but instead modifies the RNA after transcription with the 
addition of multiple rATPs at the 3’ end of the transcript. This study aims to distinguish 
the polyadenylation characteristics of MARV and RSV by first determining the poly(A) 
tail length of RSV mRNAs to lay the groundwork for the same experiment with MARV 
in a BSL-4 setting, to be performed by Adam Hume of the Mühlberger lab.  
To achieve this, mRNA was extracted from RSV-infected adenocarcinomic 
human alveolar basal epithelial cells (A549), which is similar to alveolar cells, RSV’s 
natural target, in its respiratory origin. Cells of the same line were used for each 
experiment to confound for the impact of cellular environment on polyadenylation. The 
mRNA coding for the NS-1 protein was specifically selected for analysis as it is the most 
expressed gene24(p1). Through the processes of TRIzol extraction and purification, the 
RSV virus was inactivated and the RNA purified from lysed cells and annealed to a 
deoxyribonucleic acid (DNA) primer complementary to a specific sequence at the end of 
the NS1 gene 5´ to the poly(A) tail, forming a DNA:RNA hybrid. The RNA was 
subjected to digestion with ribonuclease H (RNaseH), which would be expected to cleave 
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the gene into two pieces at the site of the DNA:RNA hybrid. From there, the cleavage 
products were denatured and subjected to polyacrylamide gel electrophoresis and 
transferred to a Nytran N membrane through northern blotting. Radiolabeled 
oligonucleotide primers, specific to either the NS-1 gene itself or the sequence preceding 
the poly(A) tail after the RNaseH cleavage site, were used to detect the cleavage 
products, which could be visualized by autoradiography and phosphorimage analysis.  
Each gel ran five or six samples. Sample one contained uninfected Mock cell 
mRNA with the digestion oligonucleotide and RNaseH, as a negative control. When 
probed, nothing should appear as the Mock cell would not produce RSV NS-1 mRNA. 
Sample two contained untreated RNA from RSV infected cells without digestion 
oligonucleotide or RNaseH, so the result should be a band at approximately 532 
nucleotides. Sample three contained only RNA from RSV infected cells and RNaseH, to 
control for any interactions between the two. The result should still be a band 
representing 532 nucleotides. Sample four and five contained RNA from RSV infected 
cells, RNaseH and the same oligonucleotides at different concentrations or different 
oligonucleotides at the same concentration. This provided information on which 
concentration of oligonucleotide is optimal for this experiment, as well as show the 
length of the gene or tail sections after digestion. The band produced by probing the NS-1 
gene upstream from the digestion primer should be slightly smaller than 532 nucleotides 
as it does not contain the poly(A) tail. The band produced by probing the sequence in 
between the digestion primer and the poly(A) tail should be a streak significantly lower 
than the others on the gel, signifying the smaller, but variable lengths of the poly(A) tail. 
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The poly(A) tail can be determined by the difference in length between untreated RNA 
from RSV infected cells and the digested tail streak or gene band, taking into 
consideration the length of the digested primer and the nucleotides between the probing 
primer of the tail and the poly(A) tail, for example. A sixth sample could contain only 
RNA from RSV infected cells and digestion oligonucleotide, to confound for any 
interactions between the two. The result should still be a band representing 532 
nucleotides without the RNaseH. 
Along with polyadenylation, mRNA secondary structure plays a key role in gene 
expression and transcription. As a result of intramolecular base pairing caused by RNA 
modifications, RNA-protein interactions, and environmental factors, mRNA secondary 
structures influence multiple levels of mRNA processing in response to change41. 
Through nuance techniques in single-nucleotide and genome-wide chemical probing, 
studies on RNA from a wide host of cells have demonstrated an evolutionary and 
molecular need to preserve these structures. So far, RNA secondary structures have been 
shown to control mRNA transcription and protein translation through ribosome pausing 
and directly influencing spliceosomes41. At the forefront, the Fearns and Mühlberger lab 
have vested interest in applying these techniques to RSV and MARV in order to 
determine secondary structures with critically valuable functions.  
In addition to poly(A) tail length determination, this study will attempt to lay 
groundwork for the uncovering the function of the stem-loop structure at the 5’ end of 
positive sense MARV mRNAs. MARV genes contain an ORF flanked by unusually long 
untranslated regions (UTRs) of 57 to 684 nucleotides33. The Mühlberger lab has 
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successfully determined that these regions of MARV mRNA contain secondary structure, 
forming stem-loop elements at the 5’ ends33. Based on computational analysis that 
predicted these secondary structures, chemical modification of mRNA in vitro in this lab 
revealed that the gs signal near the 5’ cap is always part of this stable structure42,43,44(p3). 
The significance of these stem-loop elements is demonstrated in the conservation of this 
structure across different MARV strains, even when single nucleotide substitutions are 
made (Figure 5). This structure is not characteristic of all nsNSVs, but the function of 
stem-loops within filoviruses that do contain this structure differ. Unlike studies on 
MARV, research on stem-loop structures in EBOV showed that its stem-loop secondary 
structure regulates VP30-mediated transcription . Similar studies on mammalian 
secondary structures with the same thermal stability as those of MARV so close to the 
mRNA cap did reveal, however, that stem-loops may impact post-transcriptional events 
and may greatly downregulate translation41. The fact that this structure is not always 
conserved in the negative sense RNA template additionally supports its role only after 






Figure 5; Conservation of MARV RNA secondary structure. A) Predicted stem-loop 
structures are conserved across each Musoke strain MARV protein mRNA, where base 
pairing is retained, even after single nucleotide substitutions. The gs sequences (in green) 
are consistently present within this stem-loop structure B) Predicated side by side 
comparison of the stem-loop structure of the MARV Musoke and Ravn strains 
demonstrate few nucleotide differences (indicated with blue arrows). Illustration was 
created by Elke Mühlberger. 
 
In order to analyze these phenotypes in MARV, a minigenome system will be 
utilized. This reverse genetics system already has a robust background in supporting 
research on filovirus viral infection but will be implemented here to study the effects of 
targeted gene alteration within these stem-loop regions on gene expression. Designed by 
Adam Hume of the Mühlberger lab, this study’s specific MARV bicistronic minigenome 
consists of two reporter genes, Renilla luciferase as a control for overall minigenome 
transcription, and Firefly luciferase, for determining regulation of the downstream gene 
(Figure 6). It is the incorporation of a MARV specific intergenic region between these 
genes as well as the MARV leader and trailer regions that allow the minigenome to 
represent the MARV genome for this study. This also allows for study of MARV outside 
of BSL-4 environment. Instead of coding for specific MARV proteins, the minigenome 
produces reporter proteins that emit a characteristic bioluminescence. Mutant MARV 5’ 
UTR sequences would be introduced to the downstream firefly luciferase gene to 
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determine what alterations to the primary sequence disrupt or maintain the stem-loop and 
the level of gene expression that occurs. Other experiments would replace the stem-loop 
completely with an unstructured RSV 5’ UTR. Upstream Renilla, unaffected by 
downstream mutations, will be used as a reference for Firefly luminescence, to control 
for any minigenome activity that would affect overall gene expression and luminescence. 
Using a luciferase assay, levels of luminescence can be quantified and evaluated. The 
monocistronic eGFP minigenome, containing a single eGFP reporter gene, will also be 
used to produce a bioluminescent protein that can be observed through fluorescent 
microscopy for qualitative data on gene expression (Figure 6). 
 
Figure 6; Development of Bicistronic and Monocistronic MARV minigenomes. 
Minigenomes can represent the MARV genome of interest as reporter genes flanked by 
the le and tr regions of the MARV genome, and an intergenic region, if necessary. The 
orientation of Renilla and Firefly here will give rise to upstream Renilla in the mRNA, 
which will be unaffected by changes to the 5’ UTR of the downstream firefly luciferase 





 The minigenome is transfected into cells within a cloned cDNA support plasmid 
vector, along with the required MARV nucleocapsid proteins (NP, VP35, and L) and 
VP30. VP30 is not essential for the transcription process, but has been demonstrated to 
enhance minigenome activity and expression16. pTM1 and pCAGGS plasmids represent 
two ways in which transcription of this DNA can occur (Figure 7). pTM1 plasmids 
contain a T7 promoter site which allows the T7 RNA polymerase expressed by the baby 
hamster kidney cell-line BSR-T7/5 to initiate RNA synthesis. pCAGGS plasmids are 
driven by endogenous RNA pol II within the nucleus of host cells. Newly synthesized 
MARV support proteins will then be able to transcribe and replicate the newly 
synthesized minigenome. Minigenome translation will then occur through the host cell’s 
machinery to produce bioluminescent proteins. A luminometer will then be used to 
perform a luciferase assay to quantify the level of cellular luminescence produced by 
reporter proteins.  
The objective of this study is to determine the optimal concentration and ratio of 
MARV support and minigenome plasmids, pTM1 or pCAGGS, for Firefly Luciferase 
gene expression in order to lay the foundation for further experiments. Experiments on 
the pCAGGS and pTM1 plasmids used the plasmid concentration ratios recommended by 
the Mühlberger lab to confirm a successful transfection before moving on to optimization 
(Table 1). Control plasmids, β-galactosidase, Lsyn (inactive MARV L protein), and 
mCherry will also be used in addition to the minigenome and support plasmids. A β-
galactosidase enzyme assay will be performed to normalize the data from the luciferase 
assay adjusting for minor differences in sample handling and processing inconsistencies 
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between the different samples. To control for transfection success, one well will be 
exposed to the mCherry plasmid alone, which will result in a luminescence that can be 
visualized early through fluorescent microscopy, if the transfection is successful. pTM1 
Lsyn will also be used to replace pTM1 L as a negative control for pTM1 experiments, 
inactivated by a single nucleotide substitution. Empty pCAGGS plasmid vectors will be 
used to replace pCAGGS L as a negative control for pCAGGS experiments. Lastly, an 
empty pTM1 vector will also be used to confound for any activity of the plasmid vectors 
for pTM1 experiments.  
 
Table 1; Recommended starting ratios for pTM1 and pCAGGS MARV, β-
galactosidase and minigenome plasmids. 
 pTM1 (ng) pCAGGS (ng) 
L 1000 1000 
NP 500 200 
VP35 500 50 
VP30 100 50 
β-galactosidase 200 200 




                    
Figure 7; Schematic of Minigenome Processing and Gene Expression.   
Transfected MARV pTM1 support plasmids are transcribed by the host cell’s T7 RNA 
polymerase and translated into functional support proteins. The T7 RNA polymerase also 
processes the minigenome plasmid into negative sense RNA which forms a nucleocapsid 
with the support proteins. These proteins are able to replicate the minigenome RNA by 
synthesizing the antigenome or transcribe the RNA to be further translated by the host cell 
machinery into reporter proteins. pCAGGS plasmids require an extra plasmid which 




Subsection One: Determination of RSV Poly(A) Tail Length 
RSV Viral Infection of A549 cells 
 A549 cells were grown in 100 millimeter (mm) dishes in advance by Molly Braun 
so that they would be approximately 70-80% confluent for the day of infection. One dish 
was labeled A2 to be infected, while the other was labeled Mock and left uninfected as a 
control. Once at the desired confluence, cells were then washed with 6 milliliters (ml) of 
1x Phosphate-buffered saline (PBS) and the PBS was aspirated. Biologically derived A2 
strain RSV was thawed from the -80 degrees Celsius (°C) freezer, and an infection media 
was prepared to reach a multiplicity of infection (MOI) of 3. The volume of virus stock to 
be added to the infection media for A2 was calculated by multiplying the confluence of 
the cells (%), the desired MOI and the number of cells at confluency, and then dividing 
by titre of the virus stock and 100. Molly’s virus stock prepared on July 12, 2018 had a 
titre of 1.4 x 107 plaque-forming units (PFU)/ml. Serum-free media (SFM) was then 
added to this volume reach a total infection media volume of 5 ml. This volume of 
infection media or solely SFM was added to the A2 and Mock dishes, respectively.  
TRIzol RNA Extraction 
 18 hours post-infection, cells from the A2 and Mock dishes were scraped using a 
cell scraper into 1.5 ml Eppendorf tubes and centrifuged at 7,500 x gravity (G)) for 5 
minutes at 4 °C. The tubes were aspirated of their supernatants and vortexed briefly. 1 ml 
of TRIzol was added to each and the tubes were vortexed to resuspend the pellets. The 
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supernatant was not aspirated and resuspended with TRIzol directly in the plate because 
some of the virus-infect cells of interested are not always attached to the plate. Tubes 
were incubated for 5 minutes at room temperature. Immediately after, 0.2 ml of 
chloroform was added to each. Caps were secured and the tubes were shaken vigorously 
by hand for approximately 15 seconds. Tubes were then incubated again for 2 to 3 
minutes. Samples were centrifuged at 12,000 x g for 15 minutes at 4 °C, each producing a 
lower red, phenol-chloroform phase, an interphase and a colorless upper aqueous phase, 
which contains RNA exclusively. RNA was precipitated by transferring 570 µl of this 
aqueous phase into a new Eppendorf Flex-tubes containing 0.5 ml 100% isopropanol, 
without touching the interphase. These tubes were then incubated at room temperature for 
10 minutes and then centrifuged at 12,000 x g for 10 minutes at 4 °C. RNA precipitate is 
contained with the gel-like pellet produced on the side and bottom of the tube. Using a 
P1000 pipette, most of the supernatant was removed before the tubes were spun again at 
12,000 x g for 1 minute at 4 °C. The remainder of the supernatants were removed with a 
P10 pipette. Pellets were allowed to dry briefly before 300 µl ribonuclease (RNase) free 
water (H2O) (not Diethyl pyrocarbonate (DEPC) treated) was added. Pellets were 
dissolved by allowing the tubes to stand at room temperature for several minutes and 
vortexed occasionally. 33 µl 2 moles (M) NTE buffer (NaCl 40 millimoles (mM) Tris pH 
7.4, 1 mM EDTA) was added and the tubes were vortexed. 330 µl acid-phenol (5:1 acid-
phenol:chloroform) was added and the tubes were mixed by shaking for approximately 
15 seconds. Tubes were then spun at 7000 rotations per minute (rpm) for 3 minutes at 4 
°C. 330 µl chloroform was added into fresh labeled Eppendorf tubes along with 270 µl of 
 
24 
the upper aqueous phase produced from the phenol spin. Tubes were shaken for 
approximately 15 seconds to mix. Tubes were then spun again at 7000 rpm for 3 minutes 
at 4 °C. 700 µl 100% pre-chilled ethanol with 1 ml glycogen was added to fresh labeled 
Flex-tubes and vortexed. 250 µl of the aqueous phase was added. Tube contents were 
mixed by inverting several times. Tubes were then stored at -80 °C for 2 hours. To 
precipitate the RNA, tubes were spun at full-speed (15,000 x g) for 20 minutes at 4 °C. 
RNA pellets were washed with 1 ml 70% freshly prepared, pre-chilled ethanol before 
being spun at full-speed for 20 minutes at 4 °C. Using a P1000 pipette, most of the 
supernatant was removed before the tubes were spun again at 12,000 x g for 1 minute at 4 
°C. The remainder of the supernatants were removed with a P10 pipette. RNA pellets 
were resuspended in 50 µl RNase free H2O (not DEPC treated), before being nano-
dropped and checked for 260/280 values. Tubes were freeze dried on ice before storage at 
-80 °C.  
RNeasy Kit RNA Extraction 
 RNA extraction was also accomplished by following the QIAGEN RNeasy Kit 
Protocol, according to the manufacturer’s instructions. 18 hours post-infection, cells from 
the A2 and Mock plates were scraped using a cell scraper into 15 ml tubes and 
centrifuged at 3000 x g for 5 minutes at 4 °C. Media was aspirated from each tube by 
dumping, and resuspended and washed with 5 ml 1x PBS at 4˚C before pelleting again at 
3000 x g for 5 minutes at 4 °C. Pellets were resuspended in lysis buffer RLT, according 




 Oligonucleotide primers were designed to be 20 nucleotides long complements of 
the targeted region of the NS-1 mRNA, aiming to produce the highest possible Guanine-
Cytosine percent composition with a melting temperature between 50 °C and 65 °C 
(Table 2). Primers were ordered from and manufactured by Invitrogen. Primer samples 
were diluted upon arrival with enough H2O to produce a 100 µM solution. To anneal the 
oligonucleotide primer to the extracted DNA, a 10 µM solution of oligonucleotide for 
digestion was prepared from the 100 µM solution by combining 5 µl of 100 µM stock 
with 45 µl H2O. Based on the desired concentration of oligonucleotide, 1-4 µl of either 
H2O, the 10 µM stock or the 100 µM was placed into separate 0.2 µl tubes, based on the 
study design. 5 µl RNaseH buffer and enough H2O to produce a 38 µl volume was added 
to each. Tubes were then vortexed before 10 µl of A2 RNA was added to each sample, 
except for one. The Mock sample to be added to the other tube was diluted with enough 
H2O to equal the original concentration of the A2 sample. Oligonucleotides were 
annealed to the sample RNA using a Bio-Rad CX96 Polymerase Chain Reaction 
machine. The program raised the tubes to 95 °C for 2 minutes, before decreasing the 
temperature by 1 °C each 20 seconds cycle until it reached 25 °C, where it would hold 
indefinitely. Samples were transferred to 1.5 ml Eppendorf tubes, where 2 µl RNaseH 
was added to reach a final volume of 50 µl. Tubes were then heated on a heat block for 1 
hour at 37 °C. To deactivate the RNaseH, the tubes were placed on a heat block set to 65 




Table 2; Sequence of the oligonucleotide primers designed for RNaseH digestion 
and NS-1 mRNA probing 
 
 
Phenol:Chloroform RNA Cleanup 
 These tubes were then cooled on ice for 1 minute before 200 µl of H2O containing 
0.25% sodium dodecyl sulfate (SDS) (5 µl of 10% SDS) was added and mixed. 250 µl of 
1:1 acid phenol:chloroform was added and vortexed for 30 seconds. Tubes were allowed 
to sit on ice for 5 minutes, then centrifuged at 12,000 x g for 5 minutes at room 
temperature. 210 µl of the aqueous phase was collected and added to a 1.5 ml Eppendorf 
tube containing 20 µl of NTE (2M NaCl 40mM, Tris pH 7.4, 1 mM 
trypsin/ethylenediaminetetraacetic acid (EDTA) and 2 µl of Ambion® glycoblue dye. 
Tubes were then finger mixed before 500 µl of 100% EtOH was added to precipitate the 
RNA. Tubes were vortexed and allowed to sit overnight at -20 °C. Samples were spun 
down at full-speed for 30 minutes at 4 °C. Supernatant was carefully aspirated and the 
pellet was washed with 800 µl freshly made pre-cooled 70% EtOH. Samples were 
centrifuged at full-speed for 10 minutes at 4 °C. Supernatant was carefully aspirated and 
the pellet was allowed to air-dry for 10 minutes at room temperature. 30 µl of buffer EB 




Primer Sequence (3’-5’) %GC Tm (˚C) Utility 
G56-75 AAGTGGTACTTATCAAATTC 35 49.8 NS-1 gene 
probe 





35 55.2 Digestion 
 
27 
accomplished by cooling the tubes on ice for 1 minute before following the QIAGENTM 
RNeasy MinElute Cleanup kit according to the manufacturer’s instructions. 
Formaldehyde Gel Preparation 
 Rigs were always handled with gloves, making sure to wash with a concentrated 
solution of 10% SDS and rinse with Milli-Q H2O, if needed to remove RNase 
contamination. The agarose gel casting tray was taped on either end before being placed 
in a large 11x14 inch horizontal gel rig. Wedges and tape were placed on either side of 
the casting tray and a comb was inserted. In a 250 ml glass bottle, 1.5 gram (g) agarose 
and 86.4 ml autoclaved Milli-Q H2O was microwaved until agarose particles had 
dissolved. Without cooling, in the fume hood, 10 ml 10X 3-(N-morpholino) 
propanesulfonic acid (MOPS) buffer and 3.6 ml formaldehyde was added and mixed by 
swirling gently. Before pouring the gel into the gel rig, the bottle was allowed to cool for 
1 to 2 minutes. With a clean pipet tip, bubbles that appeared in the poured gel were 
popped or dragged to the bottom of the gel. 1x MOPS buffer (10x MOPS in Milli-Q 
H2O) was poured over the gel until it was completely submerged. Samples were prepared 
with a master mix so that each tube would have 2 µl 10x MOPS buffer, 7 µl 
formaldehyde, 20 µl DI formamide, and 6.6 µl 6x loading buffer. The master mix was 
distributed to each tube before either 11 µl of ladder or 11 µl RNA with RNase free H2O 
(8 µl RNA with 3 µl H2O) was added. 46.6 µl of sample was added to the wells with the 
first lane occupied by the one containing the ladder. The gel was run at 90 volts (V) for 2 





 While the gel was running, 1 L transfer buffer was prepared by Molly Braun, 
combining 175.32 g NaCl, 8 ml 1M NaOH with H2O. To prepare the turbo blot pack, 
Whatmann Nytran N nylon was cut to 11x14 cm and left to shake in transfer buffer for 20 
to 30 minutes. Once gel had finished running, the turboblotter was assembled according 
to manufacturer’s instructions, being careful to avoid making bubbles. To ensure a flat 
surface, the gel was trimmed carefully with a fresh razor blade before placing it in the 
turboblotter. Saran wrap was placed on either side of the gel to ensure that all transfer 
buffer would interact with the gel and not passed by on the sides. The gel was transferred 
overnight to the prepared Nylon membrane using the downward capillary transfer system 
of the Turboblotter. The Nylon membrane was allowed to neutralize in 6X saline-sodium 
citrate (SSC) buffer for 15 minutes on a rocker, before being dried on filter paper until no 
more puddles were left, making sure not to over-dry.  
Oligonucleotide Primer Probing 
Ovens were heated to the desired temperature, approximately 3-5 °C lower than 
the melting temperature of the oligonucleotide primer. A Hybridization bottle was left to 
pre-warm in the ovens, along with a 50 ml conical tube containing 13.06 ml H2O. 100 µl 
of 20% SDS was added to the tube, along with 40 µl 5% NaPPi which had been heated at 
65 °C on a heat block. Pre-hybridization solution was completed by adding 6 ml 20x SSC 
and 800 µl thawed 50x Denhardt’s solution. Nylon membranes were removed from the 
rocker and placed in dry hybridization bottles using forceps. Pre-hybridization solution 
was added to each bottle and allowed to warm and rotate in the oven for 10 minutes, 
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while sheared salmon sperm DNA was heated for 5 minutes at 95 °C. 100 µl DNA of 
heated sheared salmon sperm was added directly to each bottle to give a final DNA 
concentration of 0.1 mg/ml. Bottles were allowed to pre-hybridize for one hour.  
For oligonucleotide radiolabeling, 2 μM DNA oligonucleotides (2 µl of a 10μM 
stock) was combined with 30 microcuries (µCi) 32P-γ[ATP] (Perkin Elmer), 1 µl 10X t4-
polynucleotide kinase (PNK) buffer (New England Biolabs), 3 µl of DEPC-treated H2O, 
and 1 µl t4-PNK (New England Biolabs) to a 10 µl total reaction volume, and then 
incubated at 37˚C for 30 minutes. An additional 40 µl DEPC-treated H2O was then 
added. Unincorporated 32P-γ[ATP] was removed on a GE Healthcare illustra MicroSpin 
G-25 Column (Fisher Scientific) according to manufacturer’s instructions. Labeled 
oligonucleotides were stored at -20 ̊C.  
25 µl oligonucleotide probe (prepared by Molly Braun) was added to each bottle 
and the bottles were allowed to hybridize for 6 hours. Radiation precautions such as 
placing a plexiglass screen between the bottles and the lab scientist at all times, as well as 
using a Geiger counter to detect any possible radiation contamination were utilized. 
Probe mix was poured down the drain while running water from the faucet. Blots were 
washed and rotated in the oven two times for 15 minutes with 6x SSC at the hybridization 
temperature, and then two more times for 10 minutes at room temperature. Using forceps, 
blot was removed from each bottle and dried to dampness for 10 minutes, and then 
wrapped in saran wrap. Blots were taped down inside a cassette and sealed. Cassettes 
were transported to the dark room, where an autoradiation film was placed inside the 
cassette, touching the blots. The blots were exposed with the intensifying screen 
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overnight at -80 °C. Cassettes were removed from the -80 °C freezer and allowed to thaw 
for 30 minutes. A film developer was turned on 30 minutes prior to the experiment, and a 
blank film was run. In the dark, the film was removed from the cassette and inserted into 
the developer. If the exposure was insufficient, new film was placed into the cassette and 
frozen at -80 °C. After 3 days, a new image was developed using the same method.  
Subsection Two: MARV Minigenome System 
Passaging Cells 
To maintain a constant supply of cells, BSR-T 7/5 cells were grown in a T75 flask 
at 37 °C, and 5% carbon dioxide (CO2) with Supplemented Glasgow’s Minimum 
Essential Media (GMEM) with 10% Fetal Bovine Serum (FBS) to a total medium 
volume of 15 ml. Cells were split every 3 to 4 days. Medium was removed from cells 
using a serological pipette within a tissue culture fume hood. 10 ml of PBS was added to 
and rocked gently over the cells, and then removed using another serological pipette. This 
cycle was repeated twice for a total of two washes. 1.5 ml EDTA solution was added to 
and rocked gently over the cells. The T75 flask was then placed within the incubator at 
37 °C, 5% CO2 for 90 seconds to allow cells to detach from the flask and enter the 
medium. Smacking the side of the flask allowed for further detachment of the cells. Cells 
were then resuspended in 8.5 ml Supplemented GMEM by repeated pipetting until a 
single-cell homogeneity was obtained. Approximately 10 ml of cell suspension was 
removed from the flask and saved for cell passaging and plating for transfections in a 
sterile 50 ml conical tube. From this cell suspension 500 µl was added into a T75 flask of 
fresh Supplemented GMEM with 10% FBS which results in a 1/20 dilution. This was 
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accomplished by counting the cells from the flask. 10 µl of cell suspension was added to 
10 µl of Trypan blue. Using a pipette, 10 µl of this mixture was loaded into either side of 
a hemocytometer and observed under a light microscope. Cells were counted inside of 
5x5 field of view (FOV). 82 cells counted within the FOV, for example, correspond to a 
concentration of 0.82 x 106 cells/ml. 300 µl geneticin (50 milligrams (mg)/ml) was added 
to flasks every other passage. To seed cells for transfection, 2 ml of diluted cell master 
mix from the flask was added to each well of a 6-well plate or 1 ml into each well of a 
12-well plate.  
Transformation of MARV plasmids 
To produce agar plates for growing plasmid-containing DH10β Escherichia coli 
(E. coli) cells, 4 tablets of Lysogeny Broth (LB) with agar were combined with 193.2 ml 
of Milli-Q H2O in a 250 ml container and autoclaved for approximately 1.5 hours. 
Approximately 20 ml of LB w/ agar solution is needed to cover each plate to produce a 
petri dish. 9 petri dishes are needed, one for each of our plasmids (β-galactosidase, L, 
Lsyn, mCherry, minigenome, NP, pTM1, VP30 and VP35). Once cooled, 193.2 µl thawed 
carbenicillin antibiotic, previously stored at -20 °C, was added to the container to make 
sure that only E. coli containing the plasmids in question, which feature an antibiotic 
cassette, will survive. 
In order to produce a large resource of MARV plasmids, a transformation 
protocol was followed. 50 µl E. coli-competent cells, previously stored at -80 °C, were 
distributed into nine different 14 ml conical tubes. To create tubes containing its own 
MARV plasmid, 2 µl of plasmid was added. These tubes were allowed to incubate on ice 
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for 30 minutes before being heat shocked at 42 °C for 30 seconds. Samples were further 
incubated on ice for 5 minutes before adding 450 µl Super Optimal broth with Catabolite 
repression (SOC) and shaken at 37 °C for 45 minutes. 50-150 µl of cells were plated onto 
the designated petri dishes and left overnight at 37 °C. The next day, one colony from 
each of the petri dishes was isolated and vigorously stirred into a new designated 14 ml 
conical tube containing 3 ml of LB-carbenicillin solution. Liquid LB was produced by 
combining 10 tablets of LB with 483 ml H2O in a 500 ml container and autoclaved. 
Tubes were securely capped and placed at 37 °C shaking at 220 rpm for a minimum of 5 
hours. To make larger stocks of plasmid-containing E. coli, 50 ml of LB with 
carbenicillin was added to new 250 ml Erlenmeyer flasks. 1 ml of solution from the 14 
ml conical tubes was added to each Erlenmeyer flask and returned to the shaker for a 
minimum of 5 hours.  
Glycerol Stock Production 
 To produce long-term reserves of our plasmid-containing E. coli cells, 500 µl of 
our liquid cultures, left overnight to inoculate, was added to 500 µl freshly made 50% 
glycerol in 2 ml cryovials. 50% glycerol solution was made by diluting 100% glycerol in 
distilled H2O (dH2O). Glycerol stock samples were frozen at -80 °C until needed.  
Purification of pCAGGS and pTM1 MARV Plasmids 
 Samples of MARV plasmids were purified (extracted from liquid cultures of E. 
coli cells) using the QIAGENTM Hi-Speed Plasmid Midi-Prep Kit according to the 
manufacturer’s instructions. The QIAGENTM Mini-Prep kit protocol was also used for 
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later purification of NP DNA plasmid obtained from starter cultures of 3 ml Terrific 
Broth (TB), 3 µl carbenicillin and NP plasmid, obtained from a previously made glycerol 
stock. Further attempts at purifying the NP plasmid saw some changes in the Midi Kit 
protocol. For the centrifuge steps, 2 ml tubes were used. The NP sample was divided 
amongst the needed 2 ml tubes, in turn dividing the addition of buffers and isopropanol 
into those tubes. Samples were further combined together during gravity flow of 
solutions through the QIAGENTM tip. Samples were later divided again into tubes for 
centrifugation. After this precipitation step, the formed DNA pellets were extracted from 
the tubes and combined together before being redissolved in Tris/EDTA (TE) buffer. 
Purified samples were placed under Nanodrop spectrophotometer to obtain their original 
concentration and then diluted to 100 ng/µl using RNase-free H2O to a total volume of 
200 µl. 260/280 values were also obtained through spectrophotometry to determine 
protein contaminant levels. Samples were run on a 1% agarose gel to confirm that the 
intensity of the supercoiled DNA was consistent among all samples. Samples were then 
stored at -80 °C.  
Transfection of MARV Plasmids 
 Transfections were done either in 6 or 12 well plates in a tissue culture hood. 
Master mixes for transfection of cells with the MARV support plasmids, the minigenome 
plasmid and the β-galactosidase plasmid were made in 1.5 ml Eppendorf tubes based on 
the number of wells to be infected and the experimental ratios of the plasmids. Plasmid 
volumes to be added were based on the experimental ratio of the plasmids and the size of 
the wells. In each tube, the appropriately calculated amount of DNA and a multiplication 
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factor of 150 µl GibcoTM Opti-MEMTM, without FBS and Phosphorus/Sulfur (P/S) (based 
on the number of transfections), was added. 20µL of mCherry (of 100ng/µL) was always 
added to a 6-well plate for one transfection. Extra volume of master mix is made to 
ensure that the exact needed volume can be retrieved. Eppendorf tubes were set to the 
side, and Lipofectamine (LF) master mixes were additionally prepared in 5 ml 
polystyrene falcon round-bottom tubes within the live tissue culture fume hood, one for 
each group of wells to be transfected and an additional well for the mCherry control. Per 
6-well plate, 8 µl of LF and 100 Opti-MEMTM without FBS and P/S is needed for a final 
volume of 108 µl. LF master mixes are quickly vortexed 3 times before being incubated 
at room temperature for 5 minutes. After 5 minutes, the DNA/Opti-MEMTM master mix 
was added to the polystyrene tubes containing the LF master mixes. The tubes were 
further vortexed 3 times and incubated at room temperature for 20 minutes. 5 minutes 
before the end of the incubation, media was aspirated from the incubated BSR T7/5 wells 
and washed once with 1 ml Opti-MEMTM. 0.75 ml of Opti-MEMTM without FBS and P/S 
was added. After the 20-minute incubation period, a calculated amount of solution was 
added dropwise to each well. The amount is based on the volume of LF master mix and 
DNA/Opti-MEMTM master mix needed for one transfection. Wells were then incubated at 
37 °C, 5% CO2. A 6% mix of FBS in Opti-MEM
TM was made and placed in the incubator 
to pre-warm. After a minimum of 5 hours, 0.5 ml of the 6% FBS Opti-MEMTM was 




 Transfection of wells with the monocistronic minigenome were observed directly 
under multiphoton fluorescence microscopy for green fluorescence, indicating the 
presence of eGFP reporter protein. For transfections containing the bicistronic 
minigenome, cells were harvested after 48 hours for the luciferase assay. Media within 
wells selected for luciferase assay were aspirated. Wells were then washed with 500 µl 
room temperature 1X PBS. After removal of the supernatant, 500 µl of 1X Lysis Buffer 
was added to each well. A 1X dilution was made from the 5X stock on the day of assay. 
Samples were rotated for 10 minutes. Cells were then scraped into the lysis buffer, 
transferred to 1.5 Eppendorf tubes, vortexed for 10 seconds and then centrifuged for 5 
minutes at 3000 rpm at room temperature. Supernatant was collected and diluted. 10 µl of 
each sample was diluted with 90 µl 1X Lysis Buffer to make a 1/10 dilution. 10 µl of that 
1/10 dilution was further diluted with 90 µl 1x Lysis Buffer to make a 1/100 dilution. 
Using the luminometer protocol, 50 µl of each 1/10 and 1/100 diluted samples as well as 
a blank sample of only Lysis buffer was added to the 96 well plate. Wells not selected for 
Luciferase assay (duplicates of the Luciferase wells) were observed under microscope for 
mCherry production to determine transfection success. Used samples were stored at -
20°C. 
β-galactosidase Standard Curve Determination 
Assay 2x buffer, 1x Reporter Lysis buffer and the plasmid samples were retrieved 
from -20 °C storage, allowed to thaw and sit on ice for a Promega β-galactosidase assay. 
50 µl of cell lysates were pipetted into labeled wells of a 96-well plate. To test for 
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successful transfection, a standard curve was developed using dilutions of 1x Reporter 
Lysis buffer. 10 µl of 1 u/µl β-galactosidase was added to 990 µl 1x Reporter Lysis 
buffer and vortexed. 10 µl of this 1:100 dilution was added to 990 µl of 1x Reporter Lysis 
buffer and vortexed to make a 1:10,000 stock solution. Further dilutions were made from 
this 1:10,000 stock and added to wells. All samples were mixed by pipetting the wells, 
and then 50 µl of Assay 2x buffer was added to each occupied well of the 96-well plate. 
A yellow color change is qualitatively observed and then the absorbance of the plate is 
read at 420 nm in a plate reader to test for successful transfection. 
Restriction Digestion of MARV Plasmids 
 A master mix was prepared in 1.5 ml Eppendorf tubes to ensure that 5 µl 
Cutsmart buffer and enough µl RNase-free H2O would be added to separate 1.5 ml 
Eppendorf tubes to reach a final volume of 50 µl, accounting for the volume of restriction 
enzyme and plasmid to be added. Restriction enzymes were chosen based on the 
digestion sites of the plasmid vector of interest, attempting to find a combination of 
multiple enzymes that could cut the samples into pieces that could be visualized as 
distinct, separate bands against the same ladder. Once the master mix was vortexed and 
spun down using a desktop microcentrifuge, a volume of restriction enzymes was added 
to ensure that 1 µl of each enzyme would be added to separate 1.5 ml Eppendorf tubes. 
After mixing the tube, 40 µl of the master mix was added to these 1.5 Eppendorf tubes, 
labeled for each plasmid. 10 µl of plasmid was then added to each tube. After mixing, 10 
µl of sample was pipetted up and down into 2 µl of 6x loading dye. 10 µl were then 
added to agarose gel wells with a 5 µl O’generuler 1 kb ladder occupying the first lane. 
 
37 
Agarose gels were prepared by microwaving 0.4 g agarose in 40 ml 1x Tris base/Acetic 
acid/EDTA (TAE) buffer to produce a 1% agarose gel. Once warm to the touch, the 
liquid solution was poured into a gel dock and allowed to cool to solid with an 8 well 
comb. 1x TAE buffer was poured over the gel until it was completely submerged. 
Plasmids diluted at 100 ng/µl were obtained for restriction digestion analysis. Gel was 
run at 90-110 V for approximately 50 minutes, until the bromophenol blue dye was 
observed to be ⅔ down the length of the gel. Gel was then removed from the device, and 















Subsection One: Determination of RSV Poly(A) Tail Length 
Two experiments were performed to determine the polyadenylate tail length of 
the RSV NS-1 mRNA transcript. For the first experiment, A549 cells were infected at 
85% confluency (8.8 x 107 cells) and the RNA was extracted using TRIzol extraction. 
Nanodrop analysis determined the concentration of RNA isolated from mock infected 
cells to be 218.8 ng/µl with a 260/280 of 1.89, and the concentration of RNA from RSV 
infected cells to be 106.1 ng/µl with a 260/280 of 1.83. A 260/280 value of 1.8 - 2.0 
demonstrates a relatively pure sample, free of protein contamination. Ultimately, 
additional 300 µl aliquots of RSV infected and Mock were subjected to the same method 
of TRIzol extraction, but were resuspended in 30 µl not 50 µl. Nanodrop analysis 
determined the concentration of RNA isolated from mock infected cells to be 270.6 ng/µl 
with a 260/280 of 1.92, and the concentration of RNA from RSV infected cells to be 
187.4 ng/µl with a 260/280 of 1.90. When the samples were combined, nanodrop analysis 
determined the final concentration of RNA isolated from mock infected cells to be 242.7 
ng/µl with a 260/280 of 1.89, and the concentration of RNA from RSV infected cells to 
be 137.8 ng/µl with a 260/280 of 1.87.  
This experiment was designed to probe the NS-1 gene using the radiolabeled 
primer g56-75, targeting a 20 nucleotide sequence in the leader sequence of the NS-1 
mRNA (Figure 8). For RNaseH digestion, the primer used was mrb-20, targeting a 20 
nucleotide sequence close to the poly(A) tail of the NS-1 gene (Figure 8). Six samples 
were prepared, using oligonucleotide primer concentrations based on a previous 
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experiment performed by the lab of Hardy et al. (1999) J Virol45. This experiment 
produced an image after 3 days of exposure (Figure 9).  
 
 
Figure 8; Schematic of oligonucleotide primers and their target locations on the NS-
1 gene. Above the NS-1 gene, represents the location of the digestion (purple) and 
probing (blue) oligonucleotide primers for the first experiment. The second experiment 
duplicated the first experiment for one sample, but also used the digestion and probing 
oligonucleotide primers below the NS-1 gene for the other samples, in hopes of probing 
the tail. 
 
Figure 9; Lengths of the NS-1 gene following RNaseH Digestion.  
Radiolabeled oligonucleotide g56-75 was used to probe the six samples of the NS-1 gene 
digested with mrb-20. Samples 5 and 6 differed in the concentration of mrb-20 to 
determine the better primer concentration for RNaseH digestion. Sample lanes 2-5 




This experiment was performed again, this time with a new oligonucleotide 
probe, prepared by Molly Braun. The nylon membrane was hybridized again in order to 
produce another image. This probe binds to positive sense NS-1 mRNA at the sequence 
5' GTAGACCATTAGGTTGAGAGCAATGT 3'. The resulting image was completely 
blank after a three day exposure.  
For the second experiment, A549 cells were infected at 85% confluency (8.8 x 
107 cells) and the produced RNA was extracted using the QIAGENTM RNeasy Kit. 
Nanodrop analysis determined the final concentration of RNA isolated from mock 
infected cells to be 526.2 ng/µl with a 260/280 of 2.09, and the concentration of RNA 
from RSV infected cells to be 592.1 ng/µl with a 260/280 of 2.09. For RNaseH digestion, 
the primer used was ojh-20, targeting a 20 nucleotide sequence nearer the 3’ end of the 
NS-1 mRNA. For one sample, the digestion primer used was mrb-20, targeting a 20 
nucleotide sequence close to the poly(A) tail of the NS-1 gene. This would allow for 
direct comparison of the NS-1 gene and the poly(A) tail lengths. This time, digestion 
primer concentration was increased to 0.4 µM from this first experiment due to the higher 
RNA concentration. The probing primer was mrb-20, targeting a 20 nucleotide sequence 
downstream of the digestion sequence of the NS-1 gene (Figure 8), with the exception of 
sample 5 which used g56-75, targeting a 20 nucleotide sequence upstream of the 
digestion sequence of the NS-1 gene. After probing and hybridizing the samples, as well 
as exposing the sample for three days, an image was produced (Figure 10). Streaks of 




Figure 10; Lengths of the NS-1 gene following RNaseH Digestion.  
Radiolabeled oligonucleotide mrb-20 was used to probe samples 1 to 4, while g56-75 was 
used to probe sample 5. Sample lanes 3-5 featured streaks of differing intensities.  
 
Subsection Two: MARV Minigenome System 
 Four transfections were performed using the pTM1 MARV plasmids.  
The first transfection tested the MARV plasmid concentration ratio recommended by the 
Mühlberger lab for a 6-well plate (Table 3). A luciferase assay was performed, reporting 
luciferase activity similar to the blank sample. The well containing mCherry was 
analyzed under fluorescent microscopy and demonstrated cellular luminescence (Figure 
11). A β-galactosidase assay was performed on the samples resulting in absorbance 
values for L and Lsyn (Table 3). Another luciferase assay was performed using the sample 
confirmed by Lauren Malsick to contain detectable cellular luminescence was performed, 





Figure 11; mCherry gene expression in transfected BSR-T7/5 cell. mCherry protein 
produces a red fluorescence that can be observed through fluorescent microscopy. 
mCherry protein production during this transfection indicates that overall plasmid 
transfection was successful. 
 
 Purified L, Lsyn, minigenome, NP, pTM1, VP30 and VP35 plasmids, digested 
with restriction enzymes BamHI, HindIII, and KpnI, were run on 1% agarose Figure 12). 
Digested and undigested stocks of the diluted and undiluted NP plasmid, digested with 
the same restriction enzymes, were then run on 1% agarose gels (Figure 13). New NP 
plasmids were prepared from glycerol stock and purified using the QIAGENTM Midi-
Prep kit before being digested again using the same restriction enzymes (Figure 14). 
 
Figure 12; Restriction digestion of pTM1 MARV support plasmids, empty pTM1 
vector, and bicistronic minigenome. Each plasmid, able to be cleaved by the BamHI, 
HindIII, and KpnI restriction enzymes, can be distinguished by the various band lengths. 
The experimental band lengths can also be compared to the known band lengths to check 




Figure 13; Gel electrophoresis of pTM1 NP undigested and digest stocks before and 
after dilution. Undigested NP plasmids contain bands representing the regular and 
supercoiled NP plasmid and are consistent between diluted and undiluted samples. The 
band lengths produced from BamHI, HindIII, and KpnI restriction digestion of the NP 
plasmid, are consistent between diluted and undiluted samples. 
 
 
Figure 14; Gel electrophoresis of pTM1 NP digestion. Prepared from glycerol stock 
using the Midi-Prep kit, new NP plasmids were digested by  
BamHI, HindIII, and KpnI enzymes, providing clearer band lengths. 
 
A second transfection was performed with this newly prepared NP sample, using 
the plasmid ratios for a 6-well plate (Table 3). Luciferase assay demonstrated  
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luciferase activity in our samples similar to the blank sample. A β-galactosidase assay 
was performed on the samples resulting in absorbance values for L and Lsyn (Table 3).  
New NP plasmid was obtained from the glycerol stock made by Jennifer Pacheco 
of the Mühlberger lab and prepared using the QIAGENTM Mini-Prep Kit. Diluted NP 
plasmid was run on two lanes of a 1% agarose gel, one lane with restriction enzymes 
BamHI, HindIII, and KpnI and the other with restriction enzyme AclI (Figure 15). 
 
Figure 15; Gel electrophoresis of digested pTM1 NP Plasmid using various 
restriction digestion enzymes. NP digested by BamHI-HF, HindIII-HF and KpnI-HF 
restriction enzymes are duplicated and compared to NP digestion solely by AclI. 
 
A third transfection was performed in order to test the newly prepared NP, as well 
as newly diluted MARV support plasmids with the monocistronic minigenome and a new 
bicistronic minigenome sample, obtained from Jennifer Pacheco. Four wells were 
transfected with MARV support plasmids using the same ratios as before (Table 3), such 
that two wells containing the L plasmid received either monocistronic or bicistronic 
minigenome, and the other two wells containing the Lsyn plasmid received either 
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monocistronic or bicistronic minigenome. Molly Braun also duplicated the experiment, 
using only the monocistronic minigenome. Neither of the four wells containing the 
monocistronic minigenome showed signs of eGFP luminescence under multiphoton 




Table 3. Luciferase Data and β-galactosidase Absorbance values from pTM1 
transfections at specific plasmid concentration ratio. 
 Transfection 1 Transfection 2 Transfection 3 
Plasmid Plasmid Amount Added (ng) 
pTM1-L or 
pTM1-Lsyn 500 1000 500 
pTM1-NP 250 500 250 
pTM1-VP35 250 500 250 
pTM1-VP30 50 100 50 
B-
Galactosidase 100 200 100 
Minigenome 1000 2000 1000 
Sample Blank Corrected Luciferase Data 
Lsyn (1/10 
dilution) -15 -34 n/a 
Lsyn (1/100 
dilution) -18 168 n/a 
L (1/10 
dilution) -18 -28 n/a 
L (1/10 
dilution) 122 -17 n/a 
 β-Galactosidase Absorbance (420nm) 
pTM1-L 23.0344 5.636 n/a 
pTM1-Lsyn 24.5793 5.974 n/a 
  
 Two transfections were performed using the pCAGGS MARV plasmids.  
The first transfection tested the MARV plasmid concentration ratio recommended by the 
Mühlberger lab for a 6-well plate (Table 4). A luciferase assay was performed, reporting 
 
46 
luciferase activity similar to the blank sample. A β-galactosidase assay was performed on 
the samples, resulting in an immediate color change due to a successful reaction. A 
quantitative measure was not performed. Purified pCAGGS plasmids needed for a 
successful transfection (L, minigenome, NP, VP30 and VP35) were run on 1% agarose 
gel to check for equal band intensity. 
Table 4. Luciferase Data and β-galactosidase Absorbance values from pCAGGS 
transfection using specific plasmid concentration ratio. 
Plasmid Plasmid Amount Added (ng) 






Sample Blank Corrected Luciferase Data 
pCAGGS BLANK (1/10 dilution) -17 
pCAGGS BLANK (1/100 dilution) -10 
pCAGGS-L (1/10 dilution) -9 
pCAGGS-L (1/10 dilution) -21 
β-Galactosidase Absorbance (420nm) 
pCAGGS-L n/a 
pCAGGS BLANK n/a 
 
  The last transfection attempted to test different concentrations of L plasmid in 
both pTM1 and pCAGGS using only the eGFP minigenome (Table 5). The pCAGGS 
plasmids and eGFP minigenome were prepared from glycerol stock and purified using 
the QIAGENTM Midi-Prep kit. eGFP luminescence was demonstrated in the pCAGGS 




Table 5. Plasmid Ratios for Transfection Involving Both pTM1 and pCAGGS 
Plasmids. 
pCAGGS    










1 500   250 50 250 750 
2 250   250 50 250 750 
3 50   250 50 250 750 
4   500 250 50 250 750 
pTM1   








5 1.00   200 50 50 1000 
6 0.50   200 50 50 1000 
7 0.10   200 50 50 1000 

















pCAGGS BLANK     






pCAGGS L 100 ng     






pCAGGS L 500 ng     






pCAGGS L 1000 ng     
 
 Figure 16; eGFP Protein Expression in BSR-T7/5 cells transfected with various 
levels of pCAGGS-L plasmids. Successful pCAGGS transfection occurred in samples 
containing pCAGGS-L, with a greater expression of eGFP protein luminescence in the 
500 and 1000 ng pCAGGS-L samples. No eGFP expression occurred in the sample 






Subsection One: Determination of RSV Poly(A) Tail Length 
The streaks present in the lanes containing A2 mRNA seemed to be a result of 
external RNase contamination, which would digest the mRNA into unexpected and 
various lengths. In the first experiment, the lane containing the mock sample was empty, 
which was expected as the probe would not be able to bind to anything. The expected 
band lengths for lanes 2-5 were not realized, as the streaks extended from 50 to 400 
nucleotides. The tests following the first experiment were designed to troubleshoot the 
problem and locate where the contamination might have taken place. A previously 
unused radiolabeled oligonucleotide primer was exposed to the Nylon membrane to 
determine whether the original probe was degraded or contaminated. The image was 
identical to the previous experiment, demonstrating that the primers were most likely not 
the issue, as contamination was still observed.   
Another concern was whether the RNA became contaminated during the RNA 
extraction, before RNaseH digestion. For the first experiment, the concentrations of RNA 
were low compared to the lab's usual, but the values were consistent between TRIzol 
extractions. There should be more RNA in mock tubes than infected cell tubes due to the 
ability of the healthy cells to produce more RNA. Extractions from the 300 µl aliquots 
were worse by comparison, even when the RNA was diluted in 30 µl not 50 µl. An image 
of the original stocks of purified RNA from mock and RSV infected cells, purified by 
TRIzol extraction, before RNaseH digestion was produced in order to determine when 
degradation had occurred. The image showed that RSV A2 and Mock RNA were 
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preserved and free of contamination by the time of RNA extraction (Figure 17). The band 
representing A2 was located at approximately 500 nucleotides, and the Mock sample did 
not appear. This confirmed that the concentrations and 260/280 values of the RNA were 
acceptable before RNaseH digestion.  
 
Figure 17; Band lengths of undigested A2 and Mock.  
Radiolabeled oligonucleotide g56-75 was used to probe samples 1 and 2, resulting in a 
vivid band representing NS-1 for A2 and nothing for Mock. The slight streak above the 
vivid band is a result of readthrough mRNA.  
 
To produce more RNA for the second experiment, the QIAGENTM RNeasy Kit 
was used, which resulted in a higher concentration of RNA, but the tradeoff was higher 
260/280 values of 2.09, indicative of excessive protein contamination. The TRIzol 
extraction was better at purifying the RNA, but the RNeasy Kit produced more. 
These troubleshooting efforts from the first experiment narrowed the point of 
contamination to after the original TRIzol RNA extraction. For the second experiment, 
20% SDS was used throughout the experiment to eliminate external RNases. 
Additionally, 10 µl Beta-mercaptoethanol (ß-ME) was added to the Lysis Buffer RLT of 
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the RNeasy Kit to avoid RNase degradation during cleanup. ß-ME is a reducing agent 
that denatures the intracellular RNases released during the lysis step in order to obtain 
more pure RNA samples. RLT buffer, however, does contain the denaturing agent 
guanidinium isothiocyanate (GITC), so this solution should have already been able to 
inactivate any present RNases.  
The results of the second experiment mimicked the first in that lanes 3 to 5 
featured the same streaking. Due to a shortage of mRNA from RSV infected cells, only 
half of the expected amount of RNA was to lane 2, resulting in an empty lane. The streak 
in lane 6 did parallel the expected streak formed from probing the tail, but without any 
reference due to streaks or empty lanes, no evaluation could be performed.  
Future steps in reducing contamination and protecting results would be to check 
the original stock samples for contamination before proceeding with RNaseH digestion. 
Testing the original stock samples from the first experiment was only completed after the 
first image proved contamination but would have been more beneficial before 
proceeding. Due to the time constraints of the research, no further testing could be 
completed. Since contamination seemed to occur during digestion, as the undigested 
samples were unaffected, the source of contamination may reside in the RNaseH buffer 
or the RNaseH enzyme itself. Next experiments should use new RNaseH enzyme and 
buffer to reduce the chance of contamination through these avenues. 
Once the length of the poly(A) tail is confirmed in RSV, the next step would be to 
perform the same experiment using a MARV gene. Infection and TRIzol extraction of the 
MARV gene of interest would be accomplished by Adam Hume of the Mühlberger lab in 
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a BSL-4 setting. Other variations to this experiment would be to harvest mRNA at 
different points of infection to demonstrate any differences in poly(A) tail length. This 
information could be further extended to research on readthrough mRNA, where 
intergenic poly(A) tracts could be compared to known sizes to determine if these regions 
are in fact the result of reiterative stuttering and could indicate that polyadenylation 
occurs before transcript release.  
 
Subsection Two: MARV Minigenome System 
Despite confirmation of a successful transfection in the well containing mCherry, 
minigenome reporter expression was not achieved for the first pTM1 transfection. A 
successful transfection should have produced a considerable difference in luciferase value 
between the pTM1-L plasmid sample and the blank sample from the luciferase assay. The 
values instead demonstrated that the pTM1-L sample had no change in luciferase activity 
from the pTM1-Lsyn plasmid and blank. The β-galactosidase assay confirmed that β-
galactosidase expression was produced, another indication that the plasmid transfection 
did occur. The similar values from this assay between the L and Lsyn samples 
demonstrates that there were no serious inconsistencies between the transfection rate 
between samples. Running the samples again through an additional luciferase assay along 
with samples that were previously confirmed to exhibit luciferase activity demonstrated 
that the luminometer was working properly. Ultimately, the conclusion was that 
transfection was similarly successful between L and Lsyn samples, but the MARV support 
plasmids were unable to produce minigenome reporter protein expression. Restriction 
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digestion was performed to identify whether any of the plasmids were incorrect, evident 
in a different set of band lengths, or degraded, evident in any streaking of the individual 
bands. A difference in band length would indicate a different nucleotide sequence and 
therefore a different gene. Streaking would indicate that the plasmid itself is not 
consistent between all samples as a result of degradation over time.   
Due to the blurriness of the band lengths of the NP plasmid, additional 
troubleshooting steps were performed to determine whether degradation occurred before 
or after the sample was diluted to 100 ng/µl. Digested and undigested stocks of each were 
run on 1% agarose gels, determining that all were degraded, but consistent between 
diluted and undiluted samples. Since this issue could not be ameliorated by diluting the 
original NP stock again, new NP was prepared from the glycerol stock using the 
QIAGEN Midi-Prep kit for QIAGEN-tip 100 25 ml, not the QIAGEN Hi-Speed Kit, to 
see if a new purification protocol would be successful at producing a functional NP 
plasmid. The Midi-Prep kit, though an older protocol, was historically less likely to result 
in degraded plasmid. 
The second transfection with the new NP sample was also unsuccessful. There 
was no luciferase activity detection during the luciferase assay. The β-galactosidase assay 
confirmed that β-galactosidase expression was produced, indicating that the plasmid 
transfection did occur. The similar values from this assay between the L and Lsyn samples 
demonstrates that there were no serious inconsistencies between the transfection rate 
between samples. The bands from the restriction digestion of the newly prepared NP 
plasmid did demonstrate streaking, so this result was somewhat expected. Next steps 
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were to obtain brand new NP plasmid from Jennifer Pacheco, the source of the original 
pTM1 plasmids. The sample was prepared using the Mini-Prep Kit as the process would 
be faster. The newly prepared plasmid was digested again using the regular three 
enzymes. Enzyme AclI was also used to digest the plasmid by itself in order to test to see 
if the combination of the three digestion enzymes was the cause of the streaking. The 
tighter and more vivid bands from the AclI digestion compared to the streaks produced 
by the three enzymes demonstrated that the enzymes may be interacting incorrectly with 
the NP plasmid.  
The third transfection used this NP plasmid, as well as re-diluted samples of the 
other MARV support plasmids as those samples had been thawed and refrozen many 
times and could be degraded. Molly Braun duplicated the experiment in order to test for 
human error. The monocistronic minigenome transfection in all wells did not occur. By 
this time, luciferase and β-galactosidase assays were not performed because the decision 
was made to start working on transfections using the pCAGGS plasmids, which the 
Muhlberger lab preferred. The first transfection was unsuccessful in producing any 
differences between the pCAGGS-L sample and the negative control. A β-galactosidase 
assay was performed on the samples but was not quantified because the color change was 
immediate, indicating that transfection had occurred. Lysate samples of the plasmids 
were checked for equal concentration as evident by similar band intensities under gel 
electrophoresis. The last transfection was successful in producing eGFP reporter gene 
expression, as evident by the fluorescent cells in the pCAGGS-L samples. The decision 
to decrease the eGFP minigenome concentration from 1000ng to 750ng for the pTM1 
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plasmids, came from the understanding that the minigenome was smaller than the 
bicistronic and therefore not as much would be needed. The decision to vary the 
concentration of L came from the recommendation of the Muhlberger lab.  
Preparing the pCAGGS plasmids again from glycerol stock and purifying using 
the Midi-Prep kit may have been the solution to the problem. Minigenome expression 
may have also been due to improved technique over the course of many attempts. The 
findings suggest that the concentration of pCAGGS-L plasmid plays a role in 
monocistronic eGFP minigenome expression in BSR-T7/5 cells, with the highest level of 
cellular luminescence existing in the 500ng and 1000ng pCAGGS-L wells at the ratio of 
the other pCAGGS plasmids. Regardless, the system is not optimal as the small number 
of luminescent cells from this experiment would not be helpful with informing results 
from future studies.  
A wide array of experiments could be performed next in order to obtain a more 
optimal minigenome system. Future planned experiments would include testing various 
ratios of the other pCAGGS plasmids along with the 1000ng pCAGGS-L plasmid and a 
higher concentration of bicistronic minigenome. For utilization of the bicistronic 
minigenome, the concentration should be increased to account for its larger size 
compared to the eGFP minigenome. To obtain a functioning pTM1 plasmid system, 
preparation of the MARV plasmids again might be beneficial in order to avoid any 
degraded plasmids that may be present earlier on in their creation. Despite almost five 
attempts, the pTM1 transfections were unsuccessful despite changes in pTM1-L ratios as 
well as NP plasmids themselves. Overall, these experiments took a small step toward 
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optimizing the MARV minigenome system but did more to troubleshoot potential issues 
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